Publikationen, an denen er mitarbeitet TOMAS M. M. GARCIA-CABALLERO PARADA (36)

2024

  1. Edoxaban treatment in a post-infarction experimental model

    European Journal of Pharmacology, Vol. 962

2022

  1. A genome-wide cell-free DNA methylation analysis identifies an episignature associated with metastatic luminal B breast cancer

    Frontiers in Cell and Developmental Biology, Vol. 10

  2. The Effect of Mineralocorticoid Receptor 3 Antagonists on Anti-Inflammatory and Anti-Fatty Acid Transport Profile in Patients with Heart Failure

    Cells, Vol. 11, Núm. 8

  3. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

    Frontiers in Pharmacology, Vol. 13

2021

  1. POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation

    Oncogene, Vol. 40, Núm. 15, pp. 2725-2740

2020

  1. An energy restriction-based weight loss intervention is able to reverse the effects of obesity on the expression of liver tumor-promoting genes

    FASEB Journal, Vol. 34, Núm. 2, pp. 2312-2325

2019

  1. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

    Biochemical Pharmacology, Vol. 170

2018

  1. Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis

    Virchows Archiv, Vol. 472, Núm. 2, pp. 195-203

  2. Effects of dapagliflozin on human epicardial adipose tissue: Modulation of insulin resistance, inflammatory chemokine production, and differentiation ability

    Cardiovascular Research, Vol. 114, Núm. 2, pp. 336-346

  3. Polimedication: Applicability of a computer tool to reduce polypharmacy in nursing homes

    International Psychogeriatrics, Vol. 30, Núm. 7, pp. 1001-1008

2017

  1. Liver metastasis is facilitated by the adherence of circulating tumor cells to vascular fibronectin deposits

    Cancer Research, Vol. 77, Núm. 13, pp. 3431-3441

2016

  1. FNDC5 is produced in the stomach and associated to body composition

    Scientific Reports, Vol. 6

  2. Molecular Profiling of Circulating Tumour Cells Identifies Notch1 as a Principal Regulator in Advanced Non-Small Cell Lung Cancer

    Scientific Reports, Vol. 6

  3. The role of the obestatin/GPR39 system in human gastric adenocarcinomas

    Oncotarget, Vol. 7, Núm. 5, pp. 5957-5971

2015

  1. Action of obestatin in skeletal muscle repair: Stem cell expansion, muscle growth, and microenvironment remodeling

    Molecular Therapy, Vol. 23, Núm. 6, pp. 1003-1021

  2. M-Trap: Exosome-Based Capture of Tumor Cells as a New Technology in Peritoneal Metastasis

    Journal of the National Cancer Institute, Vol. 107, Núm. 9

  3. Pit-1 inhibits BRCA1 and sensitizes human breast tumors to cisplatin and vitamin D treatment

    Oncotarget, Vol. 6, Núm. 16, pp. 14456-14471

2014

  1. Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas

    Breast Cancer Research and Treatment, Vol. 143, Núm. 1, pp. 81-89

  2. Immunohistochemical evaluation of EGFR expression in lip squamous cell carcinoma. Correlation with clinicopathological characteristics

    Histology and Histopathology, Vol. 29, Núm. 5, pp. 641-648

2013

  1. Nesfatin-1 in human and murine cardiomyocytes: Synthesis, secretion, and mobilization of GLUT-4

    Endocrinology, Vol. 154, Núm. 12, pp. 4757-4767